

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A method for the diagnosis of one or more single nucleotide polymorphism(s) in *flt-1* gene in a human, which method comprises determining the sequence of the nucleic acid of the human at one or more of positions: 1953, 3453, 3888 (each according to the position in EMBL accession number X51602 (SEQ ID No. 25)), 519, 786, 1422, 1429 (each according to the position in EMBL accession number D64016 (SEQ ID No. 27)), 454 (according to SEQ ID No. 3) and 696 (according to SEQ ID No. 5), and determining the status of the human by reference to polymorphism in the *flt-1* gene.

2. (Currently Amended) A method according to claim 1 in which the single nucleotide polymorphism at position 1953 (according to the position in EMBL accession number X51602 (SEQ ID No. 25)) is the presence of G and/or A; and/or at position 3453 (according to the position in EMBL accession number X51602 (SEQ ID No. 25)) is the presence of C and/or T; and/or at position 3888 (according to the position in EMBL accession number X51602 (SEQ ID No. 25)) is the presence of T and/or C; and/or at position 519 (according to the position in EMBL accession number D64016 (SEQ ID No. 27)) is the presence of C and/or T; and/or at position 786 (according to the position in EMBL accession number D64016 (SEQ ID No. 27)) is the presence of C and/or T; and/or at position 1422 (according to the position in EMBL accession number D64016 (SEQ ID No. 27)) is the presence of C and/or T; and/or at position 1429 (according to the position in EMBL accession number D64016 (SEQ ID No. 27)) is the presence of G and/or T; and/or at position 454 (according to the position in SEQ ID No. 3) is the presence of G and/or A; and/or at position 696 (according to the position in SEQ ID No. 5) is the presence of T and/or C.

3. (Previously Amended) A method as claimed in claim 1, wherein the nucleic acid region containing the potential single nucleotide polymorphism is amplified by polymerase chain reaction prior to determining the sequence.

4. (Previously Amended) A method as claimed in claim 1, wherein the presence or absence of the single nucleotide polymorphism is detected by reference to the loss or gain of, optionally engineered, sites recognised by restriction enzymes.

5. (Previously Amended): A method according to claim 1, in which the sequence is determined by a method selected from ARMS-allele specific amplification, allele specific hybridisation, oligonucleotide ligation assay and restriction fragment length polymorphism (RFLP).

6. (Previously Amended) A method as claimed in claim 1 for use in assessing the predisposition and/or susceptibility of an individual to diseases mediated by an flt-1 ligand.

7. (Currently Amended) A method for the diagnosis of flt-1 ligand-mediated disease, which method comprises:

- i) obtaining sample nucleic acid from an individual;
- ii) detecting the presence or absence of a variant nucleotide at one or more of positions: 1953, 3453, 3888 (each according to the position in EMBL accession number X51602 (SEQ ID No. 25)), 519, 786, 1422, 1429 (each according to the position in EMBL accession number D64016 (SEQ ID No. 27)), 454 (according to SEQ ID No. 3) and 696 (according to SEQ ID No. 5), in the flt-1 gene; and,
- iii) determining the status of the individual by reference to polymorphism in the flt-1 gene.

8. (Currently Amended) An isolated nucleic acid comprising at least 17 consecutive bases of flt-1 gene said nucleic acid comprising one or more of the following polymorphic alleles: A at position 1953 (according to X51602 (SEQ ID No. 25)), T at position 3453

(according to X51602 (SEQ ID No. 25)), C at position 3888 (according to X51602 (SEQ ID No. 25)), T at position 519 (according to D64016 (SEQ ID No. 27)), T at position 786 (according to D64016 (SEQ ID No. 27)), T at position 1422 (according to D64016 (SEQ ID No. 27)), T at position 1429 (according to D64016 (SEQ ID No. 27)), A at position 454 (according to SEQ ID No. 3) and C at position 696 (according to SEQ ID No. 5), or a complementary strand thereof.

9. (Currently Amended) An allele specific primer or probe capable of detecting an flt-1 gene polymorphism at one or more of positions: 1953, 3453, 3888 (each according to the position in EMBL accession number X51602 (SEQ ID No. 25)), 519, 786, 1422, 1429 (each according to the position in EMBL accession number D64016 (SEQ ID No. 27)), 454 (according to SEQ ID No. 3) and 696 (according to SEQ ID No. 5).

10. (Original) A primer as claimed in claim 9 which is an allele specific primer adapted for use in ARMS.

11. (Original) An allele specific nucleotide probe as claimed in claim 9 which comprises the sequence disclosed in any one of SEQ ID Nos: 6 - 14, or a sequence complementary thereto.

12. (Previously Amended) A diagnostic kit comprising one or more diagnostic primer(s) and/or allele-specific oligonucleotide probes(s) as defined in claim 9.

13. (Currently Amended) A method of treating a human in need of treatment with an flt-1 ligand antagonist drug in which the method comprises:

i) diagnosis of a single nucleotide polymorphism in flt-1 gene in the human, which diagnosis comprises determining the sequence of the nucleic acid at one or more of positions: 1953, 3453, 3888 (each according to the position in EMBL accession number X51602 (SEQ ID No. 25)), 519, 786, 1422, 1429 (each according to the position in EMBL accession number D64016 (SEQ ID No. 27)), 454 (according to SEQ ID No. 3) and 696 (according to SEQ ID No. 5);

- ii) determining the status of the human by reference to polymorphism in the *flt-1* gene; and
- iii) administering an effective amount of an *flt-1* ligand antagonist drug.

14. (Currently Amended) Use of an *flt-1* ligand antagonist drug in the preparation of a medicament for treating a VEGF-mediated disease in a human diagnosed as having a single nucleotide polymorphism at one or more of positions: 1953, 3453, 3888 (each according to the position in EMBL accession number X51602 (SEQ ID No. 25)), 519, 786, 1422, 1429 (each according to the position in EMBL accession number D64016 (SEQ ID No. 27)), 454 (according to SEQ ID No. 3) and 696 (according to SEQ ID No. 5), in the *flt-1* gene.

15. (Currently Amended) A pharmaceutical pack comprising an *flt-1* ligand antagonist drug and instructions for administration of the drug to humans diagnostically tested for a single nucleotide polymorphism at one or more of positions: 1953, 3453, 3888 (each according to the position in EMBL accession number X51602 (SEQ ID No. 25)), 519, 786, 1422, 1429 (each according to the position in EMBL accession number D64016 (SEQ ID No. 27)), 454 (according to SEQ ID No. 3) and 696 (according to SEQ ID No. 5), in the *flt-1* gene.

16. (Original) An isolated nucleic acid sequence comprising the sequence selected from the group consisting of:

- (i) the nucleotide sequence from positions 1-482 of SEQ ID No. 1;
- (ii) the nucleotide sequence from positions 616-1073 of SEQ ID No. 1;
- (iii) the nucleotide sequence from positions 1-437 of SEQ ID No. 2;
- (iv) the nucleotide sequence from positions 595-1024 of SEQ ID No. 2;
- (v) the nucleotide sequence from positions 1123-1480 of SEQ ID No. 2;
- (vi) the nucleotide sequence from positions 1-266 of SEQ ID No. 3;
- (vii) the nucleotide sequence from positions 279-726 of SEQ ID No. 3;
- (viii) the nucleotide sequence from positions 1-284 of SEQ ID No. 4;
- (ix) the nucleotide sequence from positions 391-651 of SEQ ID No. 4;
- (x) the nucleotide sequence from positions 795-1352 of SEQ ID No. 4;

- (xi) the nucleotide sequence from positions 1-579 of SEQ ID No. 5;
- (xii) the nucleotide sequence from positions 665-1256 of SEQ ID No. 5;
- (xiii) a nucleotide sequence having at least 80%, preferably at least 90%, sequence identity to a sequences (i) - (xii);
- (xiv) an isolated fragment of (i) - (xiii); and
- (xv) a nucleotide sequence fully complementary to (i) - (xiv).

17. (Currently Amended) A computer readable medium having stored thereon a nucleic acid sequence comprising at least 20 consecutive bases of the *flt-1* gene sequence, which sequence includes at least one of the polymorphisms at positions: 1953, 3453, 3888 (each according to the position in EMBL accession number X51602 (SEQ ID No. 25)), 519, 786, 1422, 1429 (each according to the position in EMBL accession number D64016 (SEQ ID No. 27)), 454 (according to SEQ ID No. 3) and 696 (according to SEQ ID No. 5).

18. (Original) A computer readable medium having stored thereon a nucleic acid comprising any of the intron sequences disclosed in any of SEQ ID Nos. 1 - 5.

19. (Currently Amended) A method for performing sequence identification, said method comprising the steps of providing a nucleic acid sequence comprising at least 20 consecutive bases of the *flt-1* gene sequence, which sequence includes at least one of the polymorphisms at positions: 1953, 3453, 3888 (each according to the position in EMBL accession number X51602 (SEQ ID No. 25)), 519, 786, 1422, 1429 (each according to the position in EMBL accession number D64016 (SEQ ID No. 27)), 454 (according to SEQ ID No. 3) and 696 (according to SEQ ID No. 5) in a computer readable medium; and comparing said nucleic acid sequence to at least one other nucleic acid sequence to identify identity.

20. (Currently Amended) The method of claim 1, wherein the nucleotides at all of the following nucleotide positions are determined: positions 1953, 3453 and 3888 as defined by the positions in EMBL accession number X51602 (SEQ ID No. 25); positions 519, 786, 1422 and 1429 as defined by the positions in EMBL accession number D64016 (SEQ ID No. 27); position

Applicant : John Craig Smith  
Serial No. : 10/621,116  
Filed : July 16, 2003  
Page : 24 of 25

Attorney's Docket No.:  
06275-276002 / LDG/Z70675-2 US

454 as defined by the position in SEQ ID No. 3; and position 696 as defined by the position in SEQ ID No. 5.